MIF Antagonist, ISO-1-CAS 478336-92-4-Calbiochem

C₁₂H₁₃NO₄

235.24

A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC₅₀ = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE₂ and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model.
A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF tautomerase activity by binding to its catalytic active site (IC₅₀ = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE₂ and COX-2 in human monocytes, and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. Also available as a 50 mM solution in DMSO (Cat. No. 505225).

Cell permeable: yes
Primary Target
MIF tautomerize
Product does not compete with ATP.
Reversible: no
Target IC₅₀: 7 µM for D-dopachrome tautomerase

Toxicity: Standard Handling (A)

Following reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Cvetkovic, I., et al. 2005. Endocrinology, 146, 2942.
Lubetsky, J.B., et al. 2002. J. Biol. Chem.277, 24976.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥98% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

light yellow

DMSO: 10 mg/mL

wet ice

−20℃

5 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 1